Boston, MA -- (SBWIRE) -- 07/15/2013 -- Cystic Fibrosis (CF) is an autosomal recessive disease characterized by the secretion of thick, sticky mucus which clogs the lungs and leads to life-threatening lung infections; and obstructs pancreatic enzyme secretions that are essential for the body to break down and absorb nutrients. CF patients have a limited number of available treatment options and significant unmet needs still exist. Opportunities are significant for new therapies that will improve symptoms, change the course of this disease, as well as increase therapy options. The introduction of the first disease modifying therapy, Kalydeco (ivacaftor), by Vertex Pharmaceuticals, paved the way for a new class of therapies known as cystic fibrosis transmembrane conductance regulator (CFTR) modulators. During our forecast period, new CFTR modulators will enter the CF market and rapid growth is forecast.

Highlights

Key Questions Answered

- What are the pressing unmet needs and remaining opportunities in CF?
- What are the R&D strategies drugmakers are pursuing in the CF therapeutics space?
- Will CFTR modulators affect the management of CF?
- How promising are these agents; and how will they shape the CF market over the coming five years?
- How will key product patent expiries in 2014 impact the CF therapeutics market?
- What unmet needs will new pipeline agents fulfil?
- What is the clinical and commercial positioning of pipeline products?

View Full Report Details and Table of Contents

Key Findings

- Rapid growth in the CF market is expected from 2012 to 2017.
- Emerging market players are employing diverse R&D strategies to gain entry in the CF market.
- A curative therapy is the most pressing unmet need in CF.
- Significant opportunities exist for new disease modifying drugs.

Scope

- Overview of CF, including epidemiology, etiology, pathophysiology, symptoms and current treatment options.
- Annualized CF therapeutics market revenue, annual cost of therapies and forecasts for five years to 2017.
- Key topics covered include strategic product assessment, market characterization, unmet needs, R&D strategies, clinical trial design and implications for the CF therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including inhaled antibiotics, CFTR modulators and pancreatic enzyme products.
- Analysis of the current and future market competition in the US and five major EU CF therapeutics market. Clinical and commercial benchmarking of promising pipeline products versus standard of care treatments and competitive assessment of all therapies. Insightful review of the key industry drivers, restraints and challenges.

Key Benefits

- Identify the unmet needs and remaining opportunities in the CF therapeutics market.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) - Opportunity Analysis and Forecasts to 2017
- Men's Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth
- Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
- Dermatology Therapeutics Market to 2017 - Alopecia Market is Forecast to Decline Due to Patent Expiry of Finasteride in 2013 and Weak Pipeline
- Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014
- Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market
- Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments
- Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists
- Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential
- Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future